Myozyme Is First FDA-Approved Inherited Muscle Disorder Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme’s Pompe disease orphan biologic was approved April 28.
You may also be interested in...
Rationing Of Genzyme’s Myozyme In Europe Likely Through April Due To Supply Constraints
Until approval of the larger 4000 L bioreactor for the Pompe Disease product, EMEA recommends priority access for infants, children and adolescents.
Rationing Of Genzyme’s Myozyme In Europe Likely Through April Due To Supply Constraints
Until approval of the larger 4000 L bioreactor for the Pompe Disease product, EMEA recommends priority access for infants, children and adolescents.
Genzyme Will Act Fast To Design Post-Market Myozyme Study By Review Date
The on-time approval of a larger production scale of Genzyme's Pompe Disease biologic Myozyme could hinge on development of a post-market study protocol prior to the Nov. 29 PDUFA date